{"entity":{"id":"nct05322590","kind":"trial","name":"BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma","aka":[],"tldr":"A phase 1/2 trial of BXQ-350 in colorectal cancer, run by Bexion Pharmaceuticals, Inc., active and no longer recruiting.","summary":"BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma is a phase 1/2 interventional study registered as NCT05322590 by Bexion Pharmaceuticals, Inc., with 195 participants enrolled, started 2023-01-09 and due to reach its primary completion in 2026-04. Interventions recorded: BXQ-350.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05322590","url":"https://clinicaltrials.gov/study/NCT05322590"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["icon-plc"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05322590","phase":"1/2","setting":"A Phase 1b/2 Placebo Controlled, Double Blinded Study on the Efficacy and Safety of BXQ-350 in Combination With mFOLFOX7 and Bevacizumab in Newly Diagnosed Metastatic Colorectal Carcinoma","sponsor":"Bexion Pharmaceuticals, Inc.","enrolled":195,"outcomes":[]},"route":"/trials/nct05322590/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"company":[{"id":"icon-plc","kind":"company","name":"ICON plc","route":"/companies/icon-plc/"}]}}